HILDER NJOROGE: Open Payments
NPI 1336877596 · LENEXA, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,426 in 187 payments from 21 companies in 2025. Trend: 2023 $2,327 · 2024 $2,638 · 2025 $3,426
Food & beverage: $3,291Education: $135
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 17 | $573 |
| ABBVIE INC. | 39 | $535 |
| Otsuka America Pharmaceutical, Inc. | 25 | $501 |
| Vanda Pharmaceuticals Inc. | 18 | $338 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 20 | $290 |
| Supernus Pharmaceuticals, Inc. | 20 | $227 |
| E.R. Squibb & Sons, L.L.C. | 3 | $144 |
| Axsome Therapeutics, Inc. | 10 | $140 |
| Janssen Pharmaceuticals, Inc | 8 | $140 |
| Neurocrine BioSciences, Inc. | 5 | $106 |
Products named: VRAYLAR, AUSTEDO XR, REXULTI, CAPLYTA, HETLIOZ, Qelbree, COBENFY, Auvelity.
Industry payments across KS — which companies pay providers there.
